Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Robert Scott who wrote (609)	1/25/1999 5:11:00 PM
From: Lel H	Read Replies (1) \| Respond to of 1139

I normally don't put a whole lot of weight into earnings for ICOS, and it appears that the market doesn't, either. For any other company, missing estimates by a quarter would send it down much farther than a buck. This information is frankly a poor indicator of the well-being of development-stage biotechs. The announcement of a phase III LeukArrest trial is a positive development, but I was hoping for a phase III announcement for IC351. Also, a cool trade name for the product would be nice. With 3 successful phase II trials which involved over 500 patients, I would expect that a phase III trial should be forthcoming.